Arrowhead Pharmaceuticals, based in Pasadena, California, develops RNA-based therapies targeting intractable diseases, employing 525 staff and featuring 14 clinical-stage investigational medicines across various therapeutic areas. Their TRiMTM platform enables tissue-specific delivery through RNA interference mechanisms.
Arrowhead Pharmaceuticals (ARWR) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Arrowhead Pharmaceuticals's actual EPS was -$1.39, missing the estimate of -$0.45 per share, resulting in a -211.38% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
